Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04342962
• Other study ID #: AML2020
• Status: Recruiting
• Phase: Phase 2
• Start date: February 16, 2021
• Est. completion date: April 2025

Study information

• Verified date: December 2021
• Source: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Contact: Paola Fazi
• Phone: 0670390528
• Email: p.fazi[@]gimema.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Non-randomized, open-label, multicenter phase II Study for the treatment of

• 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and

• 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56.

Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: April 2025
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient has evidence of AML in the peripheral blood and/or bone marrow with either BPDCN-IF [CD123/CD4/CD56 (+)] or with AML that is CD123+ but negative for either, or both, CD4 and CD56.

• The patient is =18 years old.

• The patient must be refractory to at least one previous line of conventional therapy (either high dose therapy or hypomethylating agents) or relapsed after receiving conventional therapy (a maximum of two previous line of therapy is admitted).

• The patient has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 to 2.

• The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:

1. Left ventricular ejection fraction (LVEF) =institutional lower limit of normal as measured by multigated acquisition (MUGA) scan or 2-dimensional (2-D) echocardiography(ECHO) within 21 days before start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG).

2. Serum creatinine =1.5 mg/dL (133 µmol/L).

3. Serum albumin =3.2 g/dL (32 g/L) (albumin infusions are not permitted to enable eligibility).

4. Bilirubin =1.5 mg/dL (26 µmol/L).

5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 times the upper limit of normal (ULN).

• If the patient is a woman of childbearing potential (WOCBP), she must have a negative serum or urine pregnancy test at screeningwithin 1 week before treatment.

• The patient has signed informed consent before initiation of any study-specific procedures or treatment.

• The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.

• The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 1 week after the last infusion of tagraxofusp.

Exclusion Criteria:

• The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB subtype M3).

• The patient has persistent clinically significant toxicities of Grade=2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests [as mandated in the inclusion criteria]).

• The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry.

• The patient has received treatment with an investigational agent within 14 days of study entry.

• The patient has previously received treatment with tagraxofusp.

• The patient has an active malignancy and/or cancer history (excluding antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing active malignancy will be evaluated on a case by case basis. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.

• The patient has clinically significant cardiovascular disease (eg, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).

• The patient has uncontrolled, clinically significant pulmonary disease (eg, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the opinion of the Investigator, would put the patient at significant risk for pulmonary complications during the study.

• The patient has known active or suspected central nervous system (CNS) leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.

• The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (=10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days before study treatment and there must be no evidence of Grade =2 GVHD.

• The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.

• The patient is pregnant or breastfeeding.

• The patient has known positive status for human immunodeficiency virus or active or chronic hepatitis B or hepatitis C (Patients with positive serology for HBV can be enrolled and must receive antiviral prophylaxis - i.e lamivudine or entcavir).

• The patient is oxygen-dependent.

• The patient has any medical condition that, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities.

• The patient has AML and requires more than 1 g/day of hydroxyurea (Hydroxyureaispermittedatdoses of =1 g/day.)

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• tagraxofusp
Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.

Locations

Country	Name	City	State
Italy	Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia	Bergamo
Italy	Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia	Bologna
Italy	Asst Degli Spedali Civili Di Brescia - Uo Ematologia	Brescia
Italy	Irccs Aou San Martino - Genova - Uo Clinica Ematologica	Genova
Italy	Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia	Milano
Italy	Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora	Milano
Italy	Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo	Perugia
Italy	Aou Senese - Uoc Ematologia E Trapianti	Siena

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The objective response rate (ORR)	Evaluate the activity of tagraxofusp, in terms of ORR (PR + CR + CRi), in patients with CD123+ or BlasticPlasmacytoid Dendritic Cell Neoplasm-like phenotype (BPDCN-IF) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML).	4 months
Secondary	Rate of AEs and SAEs	Safety analysis according to CTCAE criteria	28 months
Secondary	Overall survival (OS)	Overall survival	24 months
Secondary	Event Free Survival (EFS)	Event Free Survival	24 months
Secondary	Disease Free Survival (DFS)	Disease Free Survival	24 months from response assessment
Secondary	Cumulative incidence of relapse (CIR)	Cumulative incidence of relapse	24 months from response assessment
Secondary	Percentage of patients undergoing allogeneic stem cell transplantation	in MRD-negative CR	12 months